Invitae updates genetic testing offerings for cardiology, neurology

Invitae Corporation announced that the genetics information company had incorporated new research and updated eight cardiology panels and 17 neurology panels.

The panels are now available to children’s hospitals, pediatricians and medical genetics professionals, according to an Invitae news release.

For cardiology, Invitae has expanded the panels to reflect recent advances and provide evidence-based testing for diagnosing aortopathies, arrhythmias, cardiomyopathies and pulmonary hypertension. The company also added a cardiomyopathy and skeletal muscle disease panel that analyzes up to 157 genes associated with neuromuscular disorders and cardiomyopathies.

For the second quarter of 2016, Invitae had $5.6 million in sales and $23.2 million in operating expenses and posted a net loss of $24.8 million. The company also recently signed an agreement to become part of Aetna’s laboratory network starting on Aug. 15 and secured contracts with regional Blue Cross Blue Shield affiliates. As of early August, Invitae had more than 100 institutional customers.

Invitae, which is based in San Francisco, was formed in February 2012 as a wholly owned subsidiary of Genomic Health. In August 2012, Invitae merged with Locus Development, a privately held company that Genomic Health had made an investment in previously.

Invitae had an initial public offering in February 2015, and its common stock now trades on the New York Stock Exchange.